Insights

Featured

Is there a role for Ethics Committees in Pre-approval Access?

Stuart Bell, Vice President, Consulting, Inceptua Medicines Access In discussions with our clients over recent months the topic of ethics committee involvement in pre-approval access programs (expanded access, compassionate use,…
Medicines Access

Inceptua Q&A: What is Pre-Approval Access?

Typically, there are three ways in which patients can get access to a medicine; through a clinical trial, when it is commercially available, or via a pre-approval / unlicensed medicines…
Clinical Trial Services

Webinar: Strategic Comparator Sourcing in China

Optimizing the Clinical Supply Chain China is now the second-largest pharmaceutical market in the world, and with a more harmonized and efficient clinical trial approval process, it is seeing a…
Featured
Pre-approval Access
Clinical Trial Services
Safely and Reliably Supplying your Comparator Needs during COVID19
Medicines Access
Maintaining access to your medicines during COVID19
Featured
Helping get orphan drugs to patients quicker
Clinical Trial Services
How we are supporting with uninterrupted supply of medicines for clinical trials
Featured
Industry Trends in Pre-approval Access to Medicines
Medicines Access
The 21st Century Cures Act: Turn your obligations into an advantage
Update
Pre-Approval Access Policy
Clinical Trial Services
Navigating the Clinical Trial Supply Route in China
Update
Small Data for a Big Benefit
Clinical Trial Services
Inceptua Q&A: Comparator Sourcing for Clinical Trials
Medicines Access
Expediting Access to Rare Disease Therapies in Europe

News and Press Releases

Featured

Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe   

Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe       December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built…
Featured

Inceptua Partners with Global Blood Therapeutics for an Early Access Program for Voxelotor for Patients with Sickle Cell Disease

LUXEMBOURG, Dec. 3, 2020 Inceptua announces that the company has entered into a partnership with Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company focused on discovering, developing and delivering treatments…
Featured

Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

LUXEMBOURG – 25 September, 2020 – Inceptua Group  – pharmaceutical company and service partner announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Jetrea®…
Featured
Inceptua Group Announces Partnership with BioCryst on Expanded Access Program for Patients with Hereditary Angioedema
Featured
Global License Agreement a Building Block in Strategic Growth Plans
Featured
Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®
Featured
Inceptua and Portola enter exclusive distribution agreement for Ondexxya®
Featured
Inceptua appoints new Head of Asia-Pacific, Clinical Trial Services
Press release
Inceptua and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
Press release
Inceptua appoints new President North America
Press release
Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials
Press release
Inceptua appoints new CEO
News
HAEi Global Access Program Provides Life-saving Medication
Press release
Head of Global Patient Access joins Inceptua
Press release
New Chief Medical Officer joins Inceptua